Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/Δccr5) genotype is neither essential nor sufficient for protection against disease progression
✍ Scribed by Renate A. Morawetz; G. Paolo Rizzardi; Didier Glauser; Olivier Rutschmann; Bernard Hirschel; Luc Perrin; Milos Opravil; Markus Flepp; Jan von Overbeck; Michel P. Glauser; Silvia Ghezzi; Elisa Vicenzi; Guido Poli; Adriano Lazzarin
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 489 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Homozygous (Δccr5/Δccr5) and heterozygous (CCR5/Δccr5) deletions in the β‐chemokine receptor 5 (CCR5) gene, which encodes for the major co‐receptor for macrophage‐tropic HIV‐1 entry, have been implicated in resistance to HIV infection and in protection against disease progression, respectively. The CCR5/Δccr5 genotype was found more frequently in long‐term nonprogressors (LTNP) (31.0%) than in progressors (10.6%, p < 0.0001), in agreement with previous studies. Kaplan‐Meier survival analyses showed that a slower progression of disease, i.e. higher proportion of subjects with CD4^+^ T cell counts >500/μl (p = 0.0006) and a trend toward a slower progression to AIDS (p = 0.077), was associated with the CCR5/Δccr5 genotype. However, when LTNP were analyzed separetely, no significant differences in CD4^+^ T cell counts (p = 0.12) and viremia levels (p = 0.65) were observed between the wild‐type (69 % of LTNP) and the heterozygous (31.0 %) genotypes. Therefore, there are other factors which play a major role in determining the status of nonprogression in the majority of LTNP. Furthermore, there was no evidence that the CCR5/Δccr5 genotype was associated with different rates of disease progression in the group of progressors. Taken together, these results indicate that the CCR5/Δccr5 genotype is neither essential nor sufficient for protection against the progression of HIV disease.